In September of 2012, Sanofi the makers of Campath, pulled the drug from the market. Campath was originally designed to treat cancer, but it also happens to be incredibly effective in treating Multiple Sclerosis, a debilitating autoimmune disease that affects over 2.1 Million people worldwide.

The makers of Campath, Sanofi and their subsidiary Genzyme, are currently in the process of optimizing the drug for MS patients and seeking FDA approval so that this lifesaving treatment can be made available as soon as possible. However, per FDA rules, Campath has been taken off the market during this process. The U.S. Campath Distribution Program provides the drug free of charge to needy patients in the United States; however, because Mark’s disease is so unique, he does not qualify for the program.

The Mayo Clinic offered the last doses of Campath from their vault. Mark has enough medicine to keep the T-Cells at bay until the end of this month. The six doses he has taken so far have already demonstrated the worth of this treatment, for the first time in five years the doctors are sure a treatment is working.

Over the past two weeks, Sanofi has continually denied requests to supply Campath to Mark despite his doctor’s, (a M.D. PhD at the Mayo Clinic), assurances that this is the only drug available to treat his condition, and that every indication is that it can bring full remission of his symptoms. Dr. Markovic can find no scientific reason why Mark should be denied the medicine.